Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilfiker

Showing results (721-730 of 743) with videos related to

Pageof 75
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor AntagonistsJian Jin, Angel Morales-Ramos, Patrick Eidam, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
JACC. Cardiooncology|July 3, 2023
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart TissuesAnnet N Linders, Itamar B Dias, Ekaterina S Ovchinnikova, et al.
Science Translational Medicine|August 30, 2023
A blood-based marker of mitochondrial DNA damage in Parkinson's diseaseRui Qi, Esther Sammler, Claudia P Gonzalez-Hunt, et al.
European Journal of Heart Failure|December 21, 2010
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyThomas Eschenhagen, Thomas Force, Michael S Ewer, et al.
Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.
Nature|February 28, 2014
A large source of low-volatility secondary organic aerosolMikael Ehn, Joel A Thornton, Einhard Kleist, et al.
European Journal of Heart Failure|February 20, 2021
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyKaren Sliwa, Peter van der Meer, Mark C Petrie, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Circulation|April 20, 2021
Genetic and Phenotypic Landscape of Peripartum CardiomyopathyRahul Goli, Jian Li, Jeff Brandimarto, et al.
Pageof 75

Showing results (721-730 of 743) with videos related to

Sort By:
Pageof 75
ACS Medicinal Chemistry Letters|June 6, 2014
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor AntagonistsJian Jin, Angel Morales-Ramos, Patrick Eidam, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
JACC. Cardiooncology|July 3, 2023
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart TissuesAnnet N Linders, Itamar B Dias, Ekaterina S Ovchinnikova, et al.
Science Translational Medicine|August 30, 2023
A blood-based marker of mitochondrial DNA damage in Parkinson's diseaseRui Qi, Esther Sammler, Claudia P Gonzalez-Hunt, et al.
European Journal of Heart Failure|December 21, 2010
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyThomas Eschenhagen, Thomas Force, Michael S Ewer, et al.
Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.
Nature|February 28, 2014
A large source of low-volatility secondary organic aerosolMikael Ehn, Joel A Thornton, Einhard Kleist, et al.
European Journal of Heart Failure|February 20, 2021
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyKaren Sliwa, Peter van der Meer, Mark C Petrie, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Circulation|April 20, 2021
Genetic and Phenotypic Landscape of Peripartum CardiomyopathyRahul Goli, Jian Li, Jeff Brandimarto, et al.
Pageof 75